H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Ziopharm Oncology (NASDAQ: ZIOP) today and set a price target of $5.50. The company’s shares closed yesterday at $2.72, close to its 52-week low of $2.23.
“We are maintaining our Buy rating of ZIOP and our 12-month price target of $5.50 per diluted share. We derive our price target based on a risk-adjusted net present value analysis of projected product revenues until 2027 assuming a 12% discount rate and a 4% terminal growth rate. We derive an rNPV of $897M for pipeline products and add $40M in cash and cash equivalents to arrive at a 12-month price target of $5.63 per diluted share, which we round to $5.50.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 5.6% and a 40.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
Ziopharm Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
The company has a one-year high of $5.92 and a one-year low of $2.23. Currently, Ziopharm Oncology has an average volume of 1.15M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer.